Editor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- CHANGE IN RATINGS Advanced Micro Devices ( AMD - Get Report) downgraded at JMP Securities from Market Perform to Market Underperform. $4.50 price target. APU initiatives are falling flat. Ariba ( ARBA) rated new Buy at Barclays. Company should continue to gain market share. $44 price target. Comcast ( CMCSA - Get Report) rated new Buy at Brean Murray. Core cable business should outperform over the next several quarters. DirecTV ( DTV) rated new Buy at Brean Murray. $62 price target. Company can continue to grow, both in Latin and North America. Fossil ( FOSL - Get Report) rated new Overweight at JPMorgan. $150 price target. Potential for rapid global growth. Mako Surgical ( MAKO) rated new Equal-weight at Morgan Stanley. Stock is already pricing in strong growth potential. Microsemi ( MSCC) upgraded at Oppenheimer from Perform to Outperform. $28 price target. Company has solid growth visibility. Netsuite ( N) rated new Neutral at Barclays. Valuation call, based on a $45 price target. Higher One ( ONE - Get Report) upgraded at Goldman to Buy. Company should see better end-market demand. Shaw Group ( SHAW) downgraded at Baird from Outperform to Neutral. $34 price target. Company lacks near-term catalysts. SunPower ( SPWRA) downgraded at Baird from Outperform to Neutral. Valuation call, based on a $19 price target. Teradata ( TDC) downgraded at Key Banc from Buy to Hold. Valuation call as shares have enjoyed significant price appreciation. TJX Companies ( TJX) upgraded at Barclays from Equal-weight to Overweight. $64 price target. TJ Maxx sales are starting to turn around. Torchmark ( TMK) downgraded at JPMorgan from Overweight to Neutral. $44 price target. Near term trends challenging. Time Warner Cable ( TWC) rated new Hold at Brean Murray. Valuation call. Varian Medical ( VAR - Get Report) upgraded at Ticonderoga from Neutral to Buy. $84 price target. Company should not be hurt by new reimbursement plans. Whole Foods ( WFM) upgraded at Goldman from Neutral to Buy. $76 price target. Stock was also added to the Conviction List. Estimates also upped, as the company can expand its margins. End of report.